Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Tell Her Doc

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

Tell Her Doc
Site position #449

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 57.4/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +64
92
28
Dose & formulationCoreAge Rx +25
88
63
Clinical oversightCoreAge Rx +17
93
76
Labs & monitoringCoreAge Rx +38
90
52
FulfillmentCoreAge Rx +12
95
83
Contract termsCoreAge Rx +6
67
61
CoreAge Rx · top barTell Her Doc · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxTell Her Doc
WeighScore89.5/10057.4/100
GradeB+C
Site position#1#449
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$269/mo (microdose tier, plus a separate fee, compounded)
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.Not disclosed
CoverageUS only; therapy-specific state restrictions applyAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedYes
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Tell Her Doc

Site position #449 · C

Strengths

  • Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
  • Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
  • No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
  • Serves patients in all 50 states via a private online consultation

What to consider

  • 'All sales are final' — no refunds once medication has left the pharmacy
  • Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
  • References LegitScript but without an independently verifiable seal — we couldn't confirm certification
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard